返回 
加入收藏
奥氮平联合富马酸喹硫平治疗精神分裂症的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 奥氮平联合富马酸喹硫平治疗精神分裂症的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察奥氮平联合富马酸喹硫平治疗精神分裂症的疗效和安全性。方法：116例精神分裂症患者随机均分为对照组和观察组。对照组患者口服奥氮平片起始剂量5 mg，每日服药两次，5～7 d后按病情严重程度逐渐增加药物剂量，每次增加5 mg，2周内增加至5～20 mg，后维持治疗至8周。观察组患者在对照组治疗的基础上口服富马酸喹硫平片起始剂量200 mg，每日服药两次，5～7 d后按病情严重程度逐渐增加药物剂量，每次增加100 mg，2周内增加至800～1 200 mg，后维持治疗至8周。观察两组患者的临床疗效，副反应量表（TESS）评分、锥体外系反应（EPS）发生率，治疗前后认知功能评分、阳性和阴性综合征量表（PANSS）评分及不良反应发生情况。结果：观察组患者总有效率显著高于对照组，EPS发生率和治疗4周末、8周末时的TESS评分、不良反应发生率均显著低于对照组，差异均有统计学意义（P＜0.05）。治疗前，两组患者认知功能评分、PANSS评分比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者认知功能评分均显著高于同组治疗前，随治疗时间的延长逐渐升高，且观察组高于对照组；PANSS评分均显著低于同组治疗前，随治疗时间的延长逐渐降低，且观察组低于对照组，差异均有统计学意义（P＜0.05）。结论：奥氮平联合富马酸喹硫平治疗精神分裂症较单用奥氮平疗效更显著，可显著改善患者认知功能，且安全性较好。 |
| ABSTRACT： | OBJECTIVE：To observe the clinical efficacy and safety of olanzapine combined with quetiapine fumarate in the treatment of schizophrenia. METHODS： 116 patients with schizophrenia were randomly divided into observation group and control group. Control group was orally given 5 mg Olanzapine tablet by twice， then the dose was gradually increased based on severity degree after 5-7 d， each additional 5， and increased to 5-20 mg within 2 weeks， and then maintained treatment dose until 8 weeks. Observation group was additionally given 200 mg Quetiapine fumarate tablet by twice， then the dose was gradually increased based on severity degree after 5-7 d， each additional 100 mg， and increased to 800-1 200 mg within 2 weeks， and then maintained treatment dose until 8 weeks. Clinical efficacy， the cognitive function index score， positive and negative syndrome scale （PANSS） score， side effects scale （TESS） score， incidences of extrapyramidal reactions （EPS） and adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， incidence of EPS was significantly lower than control group， TESS scores in observation group were significantly lower than control group after 4 weeks and 8 weeks， incidence of adverse reactions was significantly lower than control group， the differences were statistically significant （P＜0.05）. Before treatment， there were no significant differences in the cognitive function index score and PANSS score between 2 groups（P＞0.05）； after treatment， the cognitive function index scores in 2 groups were significantly higher than before， observation group was higher than control group， and it gradually increased by the extension of treatment， PANSS scores were significantly lower than before， observation group was lower than control group， and it gradually decreased by the extension of treatment， the differences were statistically significant （P<0.05）. CONCLUSIONS： Olanzapine combined with quetiapine fumarate has better efficacy than olanzapine alone in the treatment of schizophrenia， and it can significantly improve the cognitive function index scores of patients， with good safety. |
| 期刊： | 2016年第27卷第9期 |
| 作者： | 张静，闽国庆 |
| AUTHORS： | ZHANG Jing，MIN Guoqing |
| 关键字： | 奥氮平；富马酸喹硫平；精神分裂症；疗效；认知功能；安全性 |
| KEYWORDS： | Olanzapine； Quetiapine fumarate； Schizophrenia； Efficacy； Cognitive function； Safety |
| 阅读数： | 4925 次 |
| 本月下载数： | 7 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
